Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.
Augustine Therapeutics is discovering and developing innovative medicines for the treatment of neuromuscular and neurodegeneratives diseases
Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer.
Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Biomason is a developer of a building materials technology that employs natural microorganisms to grow bio cement in ambient temperatures.
SiteOne Therapeutics develops groundbreaking non-opioid treatments for acute, neuropathic, visceral, and musculoskeletal pain.
Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.
Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases.
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
Kivu Bioscience is a biotechnology company that focuses on developing next-generation antibody-drug conjugates to target cancer.
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
Reduced develops natural flavor enhancers from upcycled produce.
Kebotix is a high-tech materials discovery and production company that reinvent the discovery of new materials using AI.
Draupnir Bio is developing a new type of cholesterol-lowering medicine which prevents blood clots in the heart.
Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.
CIRCTEC is an innovator and operator of pyrolysis technology to recycle waste into renewable fuels and circular chemicals.
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.
Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.
Novo Holdings has invested in 216 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novo Holdings's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 23 different industry categories.
Among tracked funding rounds, Harmony Biosciences received $248.0M in a Post-IPO Secondary round. Novo Holdings's total known invested capital is $18.6B.
Novo Holdings's average investment size is $86.1M across its portfolio of 216 companies.
Recent Novo Holdings portfolio additions include Hillstar Bio, Augustine Therapeutics, Callio Therapeutics, Newleos Therapeutics, Aligos Therapeutics. These companies were founded in 2020 or later.